NCT05570253 - A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 3, 2022

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions

Breast CancerMetastatic Triple-Negative Breast Cancer

Interventions

DRUG

Eribulin

Eribulin 1.4 mg/m2 IV on days 1 and 8 of an every 21 day cycle.

DRUG

SDX-7320

SDX-7320 at the dose of 49 mg/m2 SC on a Q14D basis

OTHER

Placebo

Trial Locations (10)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities), Commack

30322

NOT_YET_RECRUITING

Emory University (Data Collection Only), Atlanta

33143

RECRUITING

BAPTIST ALLIANCE - MCI (Data Collection Only), Miami

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge

07601

RECRUITING

Hackensack Meridian Health, Hackensack

07748

RECRUITING

Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale

All Listed Sponsors

collaborator

SynDevRx, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER